EQT to acquire Corza Medical's TachoSil® biosurgery business
Investment firm EQT has agreed to acquire the TachoSil® biosurgery business from Corza Medical. The deal expands EQT's portfolio in surgical products.
Private equity firm EQT has announced an agreement to acquire the TachoSil® biosurgery business from Corza Medical. TachoSil is a hemostatic and sealant patch used across a wide range of surgical specialties.
The terms of the transaction, including the purchase price, have not been disclosed. TachoSil is recognized for its ability to assist surgeons in achieving rapid bleeding control and tissue sealing, contributing to improved surgical outcomes. The product has a history of use in numerous surgical disciplines.
EQT states that the acquisition will strengthen its position within the healthcare technology sector. The firm believes that TachoSil's intellectual property and clinical evidence base will support its future growth. Corza Medical has not commented on the strategic rationale or timeline for the divestiture.
Further details regarding the completion of the acquisition are expected in the coming months. EQT will focus on integrating the business and ensuring its continued development.